Editas Medicine, Inc. (EDIT)

Editas Medicine Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-153.22	-220.43	-192.5	-115.98	-133.75
Depreciation & Amortization	6.06	6.34	5.05	3.96	2.83
Share-Based Compensation	19.8	29.29	43.4	23.16	27.24
Other Operating Activities	-4.82	7.45	-19.75	-90.98	63
Operating Cash Flow	-132.18	-177.35	-163.8	-179.84	-40.67
Capital Expenditures	-4.72	-4.1	-7.98	-7.15	-6.07
Change in Investments	0.99	118.17	-46.49	-133.37	18.32
Investing Cash Flow	-3.73	114.07	-54.47	-140.52	12.25
Share Issuance / Repurchase	118.04	1.28	282.11	224.12	131.82
Financing Cash Flow	118.04	1.28	282.11	224.12	131.82
Net Cash Flow	-17.87	-62	63.84	-96.24	103.41
Free Cash Flow	-136.9	-181.45	-171.78	-186.99	-46.73
Free Cash Flow Margin	-175.23%	-920.50%	-672.49%	-206.09%	-227.63%
Free Cash Flow Per Share	-1.80	-2.64	-2.54	-3.19	-0.94

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).